MUSE co-pay program

Meda has an affordable co-pay program for patients for whom you prescribe MUSE. Using it, patients could pay no more than $20 for their first prescriptions and no more than $40 for their next additional 11 prescriptions.

Your patients can learn about the MUSE co-pay program by visiting the U.S. consumers site. There, they will find a link to the MUSE savings program fulfillment site where they can download a co-pay card.

Note that certain conditions apply. For instance:

Both insured and non-insured patients are eligible to participate, excluding federal Medicare, Medicaid, and other federal- or state-funded programs
The offer is not valid in Massachusetts
The program expires 02/01/2013

Important Risk Information

CONTRAINDICATIONS

MUSE is contraindicated in men with any of the following:

Known hypersensitivity to alprostadil.

Abnormal penile anatomy: MUSE is contraindicated in patients with urethral stricture, balanitis (inflammation/infection of the glans of the penis), severe hypospadias and curvature, and in patients with acute or chronic urethritis.

Sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma: MUSE is contraindicated in patients who are prone to venous thrombosis or who have a hyperviscosity syndrome and are therefore at increased risk of priapism (rigid erection lasting 6 or more hours).

MUSE should not be used in men for whom sexual activity is inadvisable (see Precautions below).

MUSE should not be used for sexual intercourse with a pregnant woman unless the couple uses a condom barrier.

PRECAUTIONS

A complete medical history and physical examination should be undertaken to exclude reversible causes of erectile dysfunction prior to the initiation of MUSE therapy. In addition, underlying disorders that might preclude the use of MUSE (see Contraindications above) should be sought.

Cardiovascular effects: During in-clinic dosing, patients should be monitored for symptoms of hypotension, and the lowest effective dose of MUSE should be prescribed.

Hematologic effects: Patients administering MUSE improperly may be at risk of urethral abrasion resulting in minor bleeding or spotting. Patients on anticoagulant therapy or with bleeding disorders may be at higher risk of bleeding. Patients on anticoagulant therapy have been safely treated with MUSE; however, the risk/benefit ratio in these patients should be considered prior to prescribing MUSE.

Resumption of sexual activity: Sexual intercourse is considered a vigorous physical activity, and it increases heart rate as well as cardiac work. Physicians may want to examine the cardiac fitness of patients prior to treating erectile dysfunction.

Priapism and prolonged erection: In clinical trials of MUSE, priapism (rigid erection lasting ≥ 6 hours) and prolonged erection (rigid erection lasting 4 hours and < 6 hours) were reported infrequently (< 0.1% and 0.3% of patients, respectively). Nevertheless, these events are a potential risk of pharmacologic therapy and can cause penile injury. Physicians should lower the dose or consider discontinuing MUSE treatment in any patient who develops priapism or prolonged erection.

Drug-drug interactions: Because there are low or undetectable (< 2 picograms/mL) amounts of alprostadil found in the peripheral venous circulation following MUSE administration, systemic drug-drug interactions with MUSE are unlikely. Although formal studies have not been conducted, the concomitant use of MUSE and antihypertensive medications may increase the risk of hypotension. It is therefore advised that caution be used in the administration of MUSE to individuals on antihypertensive medications. In addition, the presence of medications in the circulation that attenuate erectile function may influence the response to MUSE.

Drug-device interactions: Use of MUSE in patients with penile implants has not been studied.

Sexual preference: There is no experience in homosexual men and no experience with other than vaginal intercourse.

WARNINGS: Because of the potential for symptomatic hypotension and syncope, which occurred in 3% and 0.4%, respectively, of patients during in-clinic dosing, MUSE titration should be carried out under medical supervision. During post-marketing surveillance, syncope occurring within 1 hour of administration has been reported. Patients should be cautioned to avoid activities, such as driving or hazardous tasks, where injury could result if hypotension or syncope were to occur after MUSE administration.

INFORMATION FOR PATIENTS: Patients should be informed that MUSE offers no protection from the transmission of sexually transmitted diseases. Patients and partners who use MUSE need to be counseled about the protective measures that are necessary to guard against the spread of sexually transmitted agents, including the human immunodeficiency virus (HIV).

Although unreported in clinical trials, there is the possibility that an overdosage of MUSE can cause priapism, a painful erection of the penis sustained for hours and unrelieved by sexual intercourse or masturbation. This condition is serious and, if untreated, it can lead to permanent inability to have an erection. Patients who experience a prolonged erection should seek prompt medical attention. Patients should be instructed how to administer MUSE. A patient package insert must be given to each patient at the initiation of MUSE therapy.

ADVERSE REACTIONS

Most frequently reported drug-related side effects include penile pain, urethral burning, urethral bleeding/spotting, testicular pain, hypotension and dizziness.